HGH Fragment 176-191 dosage by bodyweight
Reference dose ranges scaled across bodyweight bands, anchored to the most-cited research dose (250 mcg @ 75 kg). Educational only, never a recommendation.
| Bodyweight band | Reference dose range | At U-100 (1 mg/mL) | Vol. on U-100 (5 mg / 2 mL) | 5× t½ elapsed |
|---|---|---|---|---|
| <60 kg / <132 lb | 156–211 mcg | 0.16–0.21 mL | 6–8 units0.06–0.08 mL | – |
| 60–75 kg / 132–165 lb | 191–259 mcg | 0.19–0.26 mL | 8–10 units0.08–0.10 mL | – |
| 75–90 kg / 165–198 lb | 234–316 mcg | 0.23–0.32 mL | 9–13 units0.09–0.13 mL | – |
| 90–105 kg / 198–231 lb | 276–374 mcg | 0.28–0.37 mL | 11–15 units0.11–0.15 mL | – |
| >105 kg / >231 lb | 319–431 mcg | 0.32–0.43 mL | 13–17 units0.13–0.17 mL | – |
Volume column assumes a standard 5 mg vial reconstituted with 2 mL bacteriostatic water (concentration 2.5 mg/mL); insulin units shown for a U-100 syringe. No published half-life on file for HGH Fragment 176-191; the elapsed-time column is hidden.
HGH Fragment 176-191 by goal
Read HGH Fragment 176-191's profile and dosing through a specific research-goal lens.
Dose & PK references
Selected from the HGH Fragment 176-191 bibliography for relevance to dosing and pharmacokinetics.
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
- Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.